Related Experiment Video
Updated: Jul 6, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Catheter outcomes in home infusion
1Apria Healthcare. Melissa_Leone@Apria.com
Insights
Healthcare providers face challenges with intravenous catheter outcomes. New products aim to reduce catheter-related bloodstream infections (CR-BSIs), a costly issue impacting patient mortality and hospital finances.
Area of Science:
- Medical Devices
- Infection Control
- Healthcare Economics
Background:
- Intravenous (IV) catheter outcomes are critical for patients receiving IV medications.
- Numerous marketed products claim to enhance IV catheter outcomes.
- These products aim to improve patient results and lower costs linked to catheter infections and replacements.
Purpose of the Study:
- To evaluate the impact of various products on intravenous catheter outcomes.
- To assess the economic implications of catheter-related bloodstream infections (CR-BSIs).
- To understand the market for CR-BSI prevention products.
Main Methods:
- Analysis of existing literature on IV catheter outcomes and related products.
- Review of cost-benefit analyses for infection prevention strategies.
- Market research on products claiming to reduce CR-BSIs.
Main Results:
- Catheter-related bloodstream infections (CR-BSIs) incur significant costs, ranging from $5000 to $34,000 per infection.
- CR-BSIs contribute to patient mortality, accounting for 12% to 25% of bloodstream infections.
- The market for products preventing CR-BSIs represents a multi-million dollar industry.
Conclusions:
- Effective management of IV catheter outcomes is essential for healthcare providers.
- CR-BSIs pose a substantial financial and clinical burden on hospitals.
- There is a significant market demand for innovative solutions to prevent CR-BSIs.
Abstract:
Intravenous catheter outcomes are a prominent topic for healthcare providers whose patients receive intravenous medications. There are thousands of products being marketed today claiming to improve catheter outcomes, thus improving overall patient outcomes and reducing provider costs associated with catheter infections and replacement. Catheter-related bloodstream infections (CR-BSIs) cost hospitals between $5000 and $34,000 per infection, and 12% to 25% of bloodstream infections are attributable to patient mortality. Products that claim to prevent CR-BSIs and subsequently reduce the number of bloodstream infections are a multimillion-dollar industry.
Related Concept Videos
Cardiac Catheterization IV: Nursing Management
Endocarditis IV: Nursing Management
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Continuous Renal Replacement Therapy
Cardiac Catheterization I: Pre-Procedure Overview
Hemodialysis II: Procedure and Complications
